j j agree guidant deal pharmaceutical giant johnson johnson agree buy medical technology firm guidant guidant key producer equipment combat heart problem implant defibrillator pacemaker analyst say deal aim offset johnson johnson reliance slow drug business also point merger likely drug healthcare industry fragment pressure cut cost number johnson johnson product face patent expiration company also battle fierce competition generic product meanwhile demand defibrillator give heart small electric shock irregular heartbeat rhythm detect expected increase analyst say move johnson johnson widely expect firm pay guidant share wednesday closing price analyst say u antitrust regulator could force firm shed overlap stent operation stent tube use keep artery open unblock